Stallergenes Greer is a global biopharmaceutical company specialising in the diagnosis and treatment of respiratory allergies through the development and commercialisation of Allergy Immunotherapy products and services.
Our purpose is to enable precision medicine to improve life for people with allergies.
With more than 1,000 employees worldwide, a presence in 41 countries, and manufacturing facilities in both Europe and the United States, Stallergenes Greer International AG is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).
With complementary strengths, joint heritage and reputations, Stallergenes Greer is driving a continuing leadership in allergy immunotherapy.